Pangaea Data, Alexion Collaboration, Dell to Develop Supercomputer, More
By Bio-IT World Team
June 24, 2025 | Pangaea Data has entered into a collaboration agreement with Alexion to develop an Artificial Intelligence Clinical Decision Support System; Dell Technologies will develop NERSC-10, the next flagship supercomputer at the National Energy Research Scientific Computing Center; and more.
Symbiotic.blue launched to innovate a next-generation artificial intelligence-driven drug discovery (AIDD) platform by combining the power of generative AI with brain-inspired methodologies. Leveraging differentiated multi-modal data, Symbiotic.blue is developing a platform and therapeutic pipeline in parallel, beginning with obesity, in order to prioritize clinical validation. Press release.
SandboxAQ launched SAIR (Structurally Augmented IC50 Repository), the largest-ever detailed dataset of protein-ligand pairs with annotated experimental potency data. Marking a major milestone in computational drug discovery, SAIR provides an unprecedented resource for researchers to advance AI models in drug discovery, significantly enhancing the speed and accuracy of binding affinity predictions. Press release.
Dotmatics announced the launch of BioGlyph Luma, a next-generation protein design and engineering solution purpose-built for the complexity of modern biologic R&D. BioGlyph Luma helps teams create, register, and analyze diverse protein designs—including multispecific antibodies and fusion proteins—with precision, accuracy, and flexibility. Supported capabilities include asynchronous, highly scalable registration of interrelated entities, delivering traceability and information depth across the design process. Press release.
Researchers from the University of Aberdeen, Academia Sinica in Taiwan, and a group of international experts have identified that, in the nervous system, chronic pain is processed differently from the pain that comes from an injury or over exertion. They were able to differentiate between the two types of pain by genetically silencing neuronal pathways in a mouse model and then testing the theory in practice in a patient with a spinal cord injury that blocked ‘standard’ pain but spared the newly discovered pathway. Press release.
Allarity announced a research collaboration with the Indiana Biosciences Research Institute (IBRI). The collaboration is aimed primarily at further deepening the Company’s mechanistic understanding of the dual mechanism of action of stenoparib, a novel, orally available small-molecule inhibitor of PARP1/2 and tankyrase1/2. Stenoparib not only impairs DNA repair to selectively kill cancer cells but also inhibits the WNT signaling pathway, a cellular pathway commonly associated with chemoresistance and advanced-stage disease in multiple cancer types. Under the agreement, IBRI will conduct advanced molecular and cellular studies to clarify the individual and combined contributions of PARP inhibition and WNT pathway modulation to stenoparib’s observed anticancer effects. Press release.
Integrated DNA Technologies (IDT) established a synthetic biology customer solutions program, leveraging expertise to fuel research and development innovation. The program is designed to enable partnerships and agile collaboration with companies seeking custom-tailored solutions that extend beyond IDT’s catalog of synthetic biology offerings comprised of gene and gene fragments, and different vectors and plate formats for high-throughput workflows. Press release.
Bruker announced the launch of the timsOmni system, a transformative new timsTOF-based mass spectrometer designed for scientific, drug discovery, and clinical researchers, as well as for advanced QC on biologics. The platform offers structural insights into the functional or pathological proteoforms or oligonucleotides. Multimodal eXd trapping with precise electron energy control, ion accumulation, and reaction time regulation is a cornerstone innovation of the timsOmni platform. Press release.
Bruker also launched timsMetabo, a peak-performance 4D-Metabolomics mass spectrometer delivering unprecedented sensitivity, separation power and annotation confidence for small molecules, further enhanced by the novel TIMS ‘MoRE’ scan-mode. The timsMetabo system enables the generation of a ‘digital metabolome archive’ for every sample, providing TIMS-enabled qual-quant performance with greatly increased confidence for automated annotation, leveraging 4D separations and reproducible molecular collision cross sections (CCS) at scale for 4D-Metabolomics and 4D-Lipidomics. Press release.
Secretary of Energy Chris Wright announced a new contract with Dell Technologies to develop NERSC-10, the next flagship supercomputer at the National Energy Research Scientific Computing Center (NERSC), a US Department of Energy (DOE) user facility at Berkeley Lab. The new system, due in 2026, will be named after Jennifer Doudna, the Berkeley Lab-based biochemist who was awarded the 2020 Nobel Prize for Chemistry in recognition of her work on the gene-editing technology CRISPR. The new supercomputer, a Dell Technologies system powered by NVIDIA’s next-generation Vera Rubin platform, will be engineered to support large-scale high-performance computing (HPC) workloads like those in molecular dynamics, high-energy physics, and AI training and inference. Press release.